Scott L. Burrows - 01 Sep 2023 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
Chief Financial Officer
Signature
/s/ Heidy King-Jones, by power of attorney
Issuer symbol
AGLE
Transactions as of
01 Sep 2023
Transactions value $
$0
Form type
4
Filing time
05 Sep 2023, 16:10:16 UTC
Previous filing
08 Mar 2023
Next filing
22 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Stock Option (Right to Buy) Award $0 +10.1M $0.00 10.1M 01 Sep 2023 Common Stock 10.1M $0.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 10,121,441 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.